Cancer statistics in China, 2015

CA Cancer Journal for Clinicians

Volumn 66, Issue 2, 2016, Pages 115-132

  Chen, Wanqing ^a   Zheng, Rongshou ^a   Baade, Peter D ^b   Zhang, Siwei ^a   Zeng, Hongmei ^a   Bray, Freddie ^c   Jemal, Ahmedin ^d   Yu, Xue Qin ^e,f   He, Jie ^a  

^a National Cancer Center   (China)

^b CANCER COUNCIL QUEENSLAND   (Australia)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d AMERICAN CANCER SOCIETY   (United States)

^e CANCER RESEARCH DIVISION   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cancer; China; health disparities; incidence; mortality; survival; trends

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STATISTICS; CAUSE OF DEATH; CHINA; CLINICAL EFFECTIVENESS; DATA ANALYSIS; ESOPHAGUS CANCER; HEALTH CARE DELIVERY; HUMAN; LIVER CANCER; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RISK FACTOR; RURAL POPULATION; SAMPLE SIZE; STOMACH CANCER; URBAN POPULATION; ADULT; AGED; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; FEMALE; INCIDENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS; SEX RATIO; STATISTICS AND NUMERICAL DATA; STOMACH NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; CHINA; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; RISK FACTORS; RURAL POPULATION; SEX DISTRIBUTION; STOMACH NEOPLASMS; SURVIVAL RATE; URBAN POPULATION;

EID: 84960796740     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21338     Document Type: Article

References (83)

1. National Bureau of Statistics of China. China Statistical Yearbook, 2010. Beijing, China: China Statistics Press; 2010.
2. Yang L, Parkin DM, Ferlay J, Li L, Chen Y,. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005; 14: 243-250.
3. Chen W, Zheng R, Zeng H, Zhang S, He J,. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015; 27: 2-12.
4. Chen W, Zheng R, Zhang S, et al., Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014; 26: 48-58.
5. Wang L, Kong L, Wu F, Bai Y, Burton R,. Preventing chronic diseases in China. Lancet. 2005; 366: 1821-1824.
6. National Cancer Center, Disease Prevention and Control Bureau, Ministry of Health. Chinese Cancer Registry Annual Report 2012. Beijing, China: Ministry of Health; 2012.
7. Ferlay J, Burkhard C, Whelan S, Parkin DM,. Check and Conversion Programs for Cancer Registries (IARC/IACR Tools for Cancer Registries). IARC Technical Report No. 42. Lyon, France: IARC Press; 2005.
8. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X,. Report of cancer incidence and mortality in China, 2010 [serial online]. Ann Transl Med. 2014; 2: 61.
9. Chen W, Zheng R, Zhang S, et al., The incidences and mortalities of major cancers in China, 2009. Chin J Cancer. 2013; 32: 106-112.
10. International Association of Cancer Registries. International rules for multiple primary cancers. Asian Pac J Cancer Prev. 2005; 6: 104-106.
11. Li GL, Chen WQ,. Representativeness of population-based cancer registration in China-comparison of urban and rural areas. Asian Pac J Cancer Prev. 2009; 10: 559-564.
12. Chen W, Armstrong BK, Zheng R, Zhang S, Yu X, Clements M,. Cancer burden in China: a Bayesian approach [serial online]. BMC Cancer. 2013; 13: 458.
13. Yang G, Hu J, Rao KQ, Ma J, Rao C, Lopez AD,. Mortality registration and surveillance in China: history, current situation and challenges [serial online]. Popul Health Metr. 2005; 3: 3.
14. Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O, Verbeek AL, Kiemeney LA,. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011; 21: 573-577.
15. Parkin DM, Bray F,. Evaluation of data quality in the cancer registry: principles and methods. Part II. Completeness. Eur J Cancer. 2009; 45: 756-764.
16. National Cancer Institute. Joinpoint Regression Program, Version 4.2.0-April 2015. Bethesda, MD: Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute; 2015.
17. Kim HJ, Fay MP, Feuer EJ, Midthune DN,. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351.
18. Doll R, Cook P,. Summarizing indices for comparison of cancer incidence data. Int J Cancer. 1967; 2: 269-279.
19. Chen Z,. National Death Survey Report 2004-2005. Beijing, China: Peking Union Medical College Publication House; 2008.
20. Wang B, Liu SZ, Zheng RS, Zhang F, Chen WQ, Sun XB,. Time trends of ovarian cancer incidence in China. Asian Pac J Cancer Prev. 2014; 15: 191-193.
21. Li C, Yu C, Wang P,. An age-period-cohort analysis of female breast cancer mortality from 1990-2009 in China [serial online]. Int J Equity Health. 2015; 14: 76.
22. Chen W, Zheng R, Zeng H, Zhang S,. Epidemiology of lung cancer in China. Thorac Cancer. 2015; 6: 209-215.
23. Ferlay J, Soerjomataram I, Ervik M, et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. globocan.iarc.fr. Accessed June 19, 2015.
24. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015.
25. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A,. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
26. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
27. Zeng H, Zheng R, Guo Y, et al., Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2015; 136: 1921-1930.
28. Yang L, Parkin DM, Li LD, Chen YD, Bray F,. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer. 2004; 90: 2157-2166.
29. Forman D, Bray F, Brewster DH, et al. eds. Cancer Incidence in Five Continents. Vol X. IARC Scientific Publication No. 164. Lyon, France: International Agency for Research on Cancer; 2014.
30. Bray F, Parkin DM,. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009; 45: 747-755.
31. Li Q, Hsia J, Yang G,. Prevalence of smoking in China in 2010. N Engl J Med. 2011; 364: 2469-2470.
32. Yang T, Wu J, Rockett IR, Abdullah AS, Beard J, Ye J,. Smoking patterns among Chinese rural-urban migrant workers. Public Health. 2009; 123: 743-749.
33. US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
34. Anderson Johnson C, Palmer PH, Chou CP, et al., Tobacco use among youth and adults in Mainland China: the China Seven Cities Study. Public Health. 2006; 120: 1156-1169.
35. Allemani C, Weir HK, Carreira H, et al., Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385: 977-1010.
36. Ito K,. Prostate cancer in Asian men. Nat Rev Urol. 2014; 11: 197-212.
37. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA,. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 2013; 1: 47-58.
38. Baade PD, Youlden DR, Krnjacki LJ,. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009; 53: 171-184.
39. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al., Challenges to effective cancer control in China, India, and Russia. Lancet Oncol. 2014; 15: 489-538.
40. Varghese C, Shin HR,. Strengthening cancer control in China. Lancet Oncol. 2014; 15: 484-485.
41. Li L, Ji J, Wang JB, Niyazi M, Qiao YL, Boffetta P,. Attributable causes of breast cancer and ovarian cancer in China: reproductive factors, oral contraceptives and hormone replacement therapy. Chin J Cancer Res. 2012; 24: 9-17.
42. Wang B, He M, Chao A, Engelgau MM, Saraiya M, Wang L,. Cervical cancer screening among adult women in China, 2010. Oncologist. 2015; 20: 627-634.
43. Zhao FH, Lewkowitz AK, Hu SY, et al., Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012; 131: 2929-2938.
44. Forman D, de Martel C, Lacey CJ, et al., Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30 (suppl 5): F12-F23.
45. Li S, Hu T, Lv W, et al., Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China: a study of 10,012 cases from a nationwide working group. Oncologist. 2013; 18: 1101-1107.
46. Kahn C, Simonella L, Sywak M, Boyages S, Ung O, O'Connell D,. Pathways to the diagnosis of thyroid cancer in New South Wales: a population-based cross-sectional study. Cancer Causes Control. 2012; 23: 35-44.
47. Kilfoy BA, Zheng T, Holford TR, et al., International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009; 20: 525-531.
48. Morris LG, Sikora AG, Tosteson TD, Davies L,. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013; 23: 885-891.
49. Pandeya N, McLeod DS, Balasubramaniam K, et al., Increasing thyroid cancer incidence in Queensland, Australia 1982-2008-true increase or overdiagnosis [published online ahead of print February 17, 2015 ]? Clin Endocrinol (Oxf). doi: 10.1111/cen.12724.
50. Brito JP, Morris JC, Montori VM,. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours [serial online]. BMJ. 2013; 347: f4706.
51. Xie SH, Chen J, Zhang B, et al., Time trends and age-period-cohort analyses on incidence rates of thyroid cancer in Shanghai and Hong Kong [serial online]. BMC Cancer. 2014; 14: 975.
52. Xiang W, Shi JF, Li P, et al., Estimation of cancer cases and deaths attributable to infection in China. Cancer Causes Control. 2011; 22: 1153-1161.
53. Li RC, Yang JY, Gong J, et al., Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma [article in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004; 25: 385-387.
54. Chang MH, Chen CJ, Lai MS, et al., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336: 1855-1859.
55. Yu SZ, Chen G, Zhi XL, Li J,. Primary liver cancer: natural toxins and prevention in China. J Toxicol Sci. 1998; 23 (suppl 2): 143-147.
56. Liang X, Bi S, Yang W, et al., Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27: 6550-6557.
57. Wang JB, Jiang Y, Liang H, et al., Attributable causes of cancer in China. Ann Oncol. 2012; 23: 2983-2989.
58. Chen ZM, Peto R, Iona A, et al., Emerging tobacco-related cancer risks in China: a nationwide, prospective study of 0.5 million adults. Cancer. 2015; 121 (suppl 17): 3097-3106.
59. Zhang J, Ou JX, Bai CX,. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology. 2011; 16: 1165-1172.
60. Chen Z, Peto R, Zhou M, et al., Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies. Lancet. 2015; 386: 1447-1456.
61. Youlden DR, Cramb SM, Baade PD,. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008; 3: 819-831.
62. Zhi XY, Zou XN, Hu M, Jiang Y, Jia MM, Yang GH,. Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005: an adverse health effect from exposure to smoking. Cancer. 2015; 121 (suppl 17): 3107-3112.
63. Yang G, Wang Y, Wu Y, Yang J, Wan X,. The road to effective tobacco control in China. Lancet. 2015; 385: 1019-1028.
64. Paskett ED, Bernardo BM, Khuri FR,. Tobacco and China: the worst is yet to come. Cancer. 2015; 121 (suppl 17): 3052-3054.
65. Hu Y, Sun X, Yuan Z, Dong W, Zhang J,. Another step change for tobacco control in China? Lancet. 2015; 386: 339-340.
66. Will China make the great leap in tobacco control in 2015 [editorial]? Lancet. 2015; 385: 2122.
67. Zhang J, Mauzerall DL, Zhu T, Liang S, Ezzati M, Remais JV,. Environmental health in China: progress towards clean air and safe water. Lancet. 2010; 375: 1110-1119.
68. Gao H,. Chinese Government admits existence of cancer villages [serial online]. Lancet Oncol. 2013; 14: 284.
69. Ministry of Environmental Protection. China to spend trillions on pollution battle. english.mep.gov.cn/News-service/media-news/201307/t20130729-256489.htm#. Accessed October 13, 2015.
70. Kang LN, Qiao YL,. Cancer screening and prevention in China [serial online]. Cancer Control 2014. 2014: 131-133. cancercontrol.info/wp-content/uploads/2014/08/131-133-Qiao-cc2014.pdf. Accessed October 8, 2015.
71. Harford JB,. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol. 2011; 12: 306-312.
72. Wei WQ, Chen ZF, He YT, et al., Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China. J Clin Oncol. 2015; 33: 1951-1957.
73. Valdez M, Jeronimo J, Bansil P, et al., Effectiveness of novel, lower-cost molecular human papillomavirus-based tests for cervical cancer screening in rural China [published online ahead of print September 30, 2015 ]. Int J Cancer. doi: 10.1002/ijc.29877.
74. Hong QY, Wu GM, Qian GS, et al., Prevention and management of lung cancer in China. Cancer. 2015; 121 (suppl 17): 3080-3088.
75. Aberle DR, Adams AM, Berg CD, et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
76. Sullivan R, Alatise OI, Anderson BO, et al., Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015; 16: 1193-1224.
77. Meng Q, Xu L,. Monitoring and evaluating progress towards Universal Health Coverage in China [serial online]. PLoS Med. 2014; 11: e1001694.
78. Yip WC, Hsiao WC, Chen W, Hu S, Ma J, Maynard A,. Early appraisal of China's huge and complex health-care reforms. Lancet. 2012; 379: 833-842.
79. Alcorn T,. Balancing priorities in China's expanding health-care system [serial online]. Lancet Oncol. 2012; 13: 975.
80. Walters S, Maringe C, Butler J, et al., Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer. 2013; 108: 1195-1208.
81. Yu XQ, O'Connell DL, Forman D,. Comparison of cancer survival in UK and Australia: rates are higher in Australia for three major sites. Br J Cancer. 2004; 91: 1663-1665.
82. Ferlay J, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR,. Cancer Incidence in Five Continents, Volumes I to IX: IARC CancerBase No. 9 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. ci5.iarc.fr. Accessed June 29, 2015.
83. Ellis L, Woods LM, Esteve J, Eloranta S, Coleman MP, Rachet B,. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014; 135: 1774-1782.